Roche's Atezolizumab Gets CDF Place For Bladder Cancer
Executive Summary
Roche may have stolen a march on other checkpoint inhibitors in Europe's bladder cancer market by gaining a Cancer Drugs Fund place for Tecentriq in final draft guidance from England's health technology assessment body, NICE.
You may also be interested in...
NICE Invites Tesaro To Put Zejula Into Cancer Drugs Fund
Tesaro's PARP inhibitor for ovarian cancer has not been recommended for routine use on the NHS, but NICE has suggested that the company try the Cancer Drugs Fund route.
Imfinzi EU Bladder Cancer Filing On Back Burner As AZ Focuses On Lung
The CHMP decided against an accelerated review of Imfinzi in both bladder and lung cancer but unlike in the case of NSCLC, AstraZeneca has not filed for the former indication.
Bladder Cancer Market Wide Open As Tecentriq Fails Confirmatory 2L Trial
A cloud hangs over the approval of Roche's Tecentriq in the second line treatment of bladder cancer following the failure of a confirmatory Phase III trial. Meanwhile, rival product Bavencio from Merck KGaA and Pfizer has been granted accelerated approval by the FDA.